Golocdacimab is under clinical development by AstraZeneca and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease). According to GlobalData, Phase II drugs for Coronary Artery Disease (CAD) (Ischemic Heart Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Golocdacimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Golocdacimab overview
Golocdacimab (MEDI-6570) is under development for the treatment of type 2 diabetes, myocardial infarction (MI), atherosclerosis and coronary artery disease (CAD). The drug candidate acts by targeting LOX-1. The drug candidate is a monoclonal antibody. It is a new molecular entity. It is administered through subcutaneous route. The drug candidate was also under development for the treatment for type 2 diabetes and atherosclerosis.
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Golocdacimab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.